8-Hydroxy-2′-deoxyguanosine (8-OHdG) as a possible marker of arsenic poisoning: a clinical case study on the relationship between concentrations of 8-OHdG and each arsenic compound in urine of an acute promyelocytic leukemia patient being treated with arsenic trioxide

Arsenic trioxide (ATO) is an effective therapeutic agent for acute promyelocytic leukemia (APL). In the present study, the concentrations of 8-hydroxy-2′-deoxyguanosine (8-OHdG) and arsenic compounds [(dimethylarsinic acid (DMA), monomethylarsonic acid (MMA), As(V), and As(III)] in urine of an APL patient were determined during ATO treatment. The concentrations of 8-OHdG, DMA, and MMA were increased, especially during the fi rst consolidation therapy. Signifi cant positive correlations were observed between concentrations of 8-OHdG and DMA, between concentrations of 8-OHdG and MMA, and between concentrations of 8-OHdG and the sum of arsenic compounds. The present study supports the idea that urinary 8-OHdG can be a marker for arsenic poisoning, when it is detected together with DMA and MMA. In addition, this study is the fi rst to show the relationship between 8-OHdG and levels of arsenic compounds in urine of an APL patient being treated with ATO.